马应龙：10月28日召开董事会会议

Group 1 - The company, Mayinglong (SH 600993), announced its 11th 22nd board meeting held on October 28, 2025, via telecommunication, where the "2025 Q3 Report" and other documents were reviewed [1] - For the first half of 2025, the revenue composition of Mayinglong was as follows: pharmaceutical manufacturing accounted for 62.47%, pharmaceutical commerce for 30.62%, and hospital diagnosis and treatment for 10.65%, with undistributed amounts at 0.23% and internal offsets at -3.98% [1] - As of the report date, Mayinglong's market capitalization stood at 11.7 billion yuan [1]